LifeVantage Corporation announced its financial results for the first quarter of fiscal 2026. Revenue during the period improved 0.7% year-over-year to $47.6 million. The Americas and Asia-Pacific & Europe regions saw revenue increases of 0.8% and 0.4% respectively. When excluding foreign currency fluctuations, Asia-Pacific and Europe experienced a 1.4% revenue decrease compared to the same period last year.
Gross profit for the first quarter of fiscal 2026 was $37.8 million, or 79.5% of revenue, compared to $37.7 million and 79.9% of revenue in the same period of fiscal 2025. Shipping and warehouse-related expenses were the primary driving factors for this slight dip in gross profit as a percentage of revenue.
Operating income during the period was $2.3 million, compared to $2.6 million in fiscal Q1 2025. Net income for the period was $2.2 million, or $0.17 per diluted share, up from $1.8 million and $0.14 per diluted share in fiscal Q1 2025. Adjusted EBITDA was $3.9 million, down from $4.4 million in the same period last year.
“The first quarter marked a pivotal milestone for LifeVantage as we focused on closing our strategic acquisition of LoveBiome, positioning us as a leader at the intersection of two rapidly expanding wellness markets: natural GLP-1 activation and microbiome health,” said Steve Fife, LifeVantage President and CEO. “We’re seeing several encouraging trends that should drive accelerating growth as we scale our combined operations and realize the full benefits of our strategic investments. The integration of LoveBiome’s passionate consultant community along with their flagship P84 product is already exceeding expectations and momentum is building across our business. With a comprehensive wellness ecosystem that addresses multiple aspects of human health through scientifically validated activation technologies, we are uniquely positioned to serve the evolving needs of consumers worldwide.”
The company ended the period with cash and cash equivalents of $13.1 million, down from $20.2 million sequentially, with no outstanding debt. Full-year fiscal 2026 financial guidance now includes revenue between $225 million to $240 million with an adjusted EBITDA between $23 million to $26 million.
